Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Transmission and prevention news

Show

From To
Healthy dose of hope for one-use syringes

The people of the farming community of Roka in Cambodia are living through exactly the nightmare scenario that the World Health Organisation wants to stamp out with a new policy on syringes. In wooden huts and farmhouses dotted among paddy fields, families are struggling to cope with the bombshell of a sudden and frightening mass infection of HIV.

Published
23 February 2015
From
BBC
Clinicians report two acute HCV infections in Kaiser San Francisco PrEP programme

Two HIV-negative gay men receiving HIV pre-exposure prophylaxis (PrEP) through Kaiser Permanente in San Francisco were newly infected with hepatitis C virus (HCV), with sex being their only

Published
22 February 2015
By
Liz Highleyman
"Nous sommes PrEP", new French PrEP advocacy organisation, announced in anticipation of IPERGAY study results (press release in French)

A new French PrEP advocacy organisation has been founded in anticipation of high effectiveness results to be announced in the French IPERGAY trial of PrEP at the CROI conference on Tuesday. 'Nous Sommes PrEP' (We Are PrEP) say: "The effectiveness of PrEP against HIV in individuals particularly at risk of infection will be proven and made public. From February 25, we will demand that health authorities provide PrEP as quickly as possible to have a new effective way to curb the epidemic."

Published
22 February 2015
From
IPERGAY
HIV testing continues to rise in UK gay men, but safer sex knowledge drops

With health services and HIV prevention organisations now having relentlessly focused on HIV testing for several years, new data suggest that more English gay men have recently

Published
20 February 2015
By
Roger Pebody
University of RochesterTests HIV Vaccine Pill

Researchers at the University of Rochester Medical Center are testing a new oral vaccine to prevent infection with HIV, the virus that causes AIDS. The vaccine is unique because it is given as a pill, unlike most HIV vaccines tested to date that have been given as shots.

Published
20 February 2015
From
University of Rochester press release
NIH-sponsored HIV vaccine trial launches in South Africa

A clinical trial has launched in South Africa to study an investigational HIV vaccine regimen for safety and the immune responses it generates in volunteers. This experimental regimen is based on the one tested in the RV144 trial - -the first to demonstrate that a vaccine can protect people from HIV infection -- but is designed to potentially provide greater protection and is adapted to the predominant HIV subtype in southern Africa.

Published
19 February 2015
From
Eurekalert Medicine & Health
PrEP Enrollment: Where Are the Young Black Guys?

Out of all gay and bisexual men in the U.S., the highest percent of new HIV infections occur in African American men. Yet the number of African American men accessing pre-exposure prophylaxis (PrEP) to prevent HIV may be lower than men of other demographics.

Published
19 February 2015
From
BETA blog
Experimental AIDS Drug Stirs Talk Of Vaccine 'Alternative'

For more than three decades, scientists have tried unsuccessfully to develop an effective vaccine for HIV, the virus that causes AIDS. But now researchers say they have created an experimental drug that may function as a sort of "alternative" vaccine for the virus. The experimental drug, a protein known as eCD4-IG, blocks infection by keeping the virus from binding to the immune cells that are the virus's target. In tests on monkeys, the drug "candidate" proved to be extremely effective at blocking infection--even with the most virulent strains of HIV and its simian counterpart, SIV.

Published
19 February 2015
From
Huffington Post
Gilead's Pill Can Stop HIV. So Why Does Almost Nobody Take It?

There are many reasons: Gilead says PrEP isn’t a moneymaker, so the drugmaker doesn’t pitch the medicine to many of the primary care doctors who see healthy, HIV-negative gay men most likely to benefit from Truvada. Patients and advocates say doctors often don’t know about the medicine, and some insurance plans leave patients with copays as high as $1,300, making use by the healthy less affordable.

Published
19 February 2015
From
Bloomberg
York trials new HIV prevention method

Scientists at the University of York, in conjunction with the York Clinical Research Facility, will start the first phase of trials looking into a new way to prevent HIV transmission.

Published
18 February 2015
From
HIV / AIDS News From Medical News Today

Filter by country